Noteworthy Numbers: Acute Lymphocytic Leukemia

TOP - March 2020, Vol 13, No 2 - Leukemia

Leukemia is the most frequently diagnosed cancer in children and adolescents, representing approximately 1 of 3 cancers in these populations of patients. Of the 4 main types of leukemia (acute myeloid leukemia, acute lymphocytic leukemia [ALL], chronic myeloid leukemia, and chronic lymphocytic leukemia), ALL is the most common type found in children and adolescents. The following provides key statistics and other helpful information regarding ALL.

The American Cancer Society estimates that approximately 6150 new cases of ALL will be diagnosed in the United States in 2020, and approximately 1520 deaths will be attributed to the disease in the same year. Although most cases of ALL occur in children, 4 of 5 deaths related to the disease occur in adults.1

The National Cancer Institute reports that the overall incidence of pediatric cancer, including ALL, has been slowly on the rise since 1975.2 Incidence peaks sharply in young children (>90 cases per 1 million per year in those aged 2 to 3 years vs <30 cases per 1 million by age 8 years). The incidence of ALL is highest in Hispanic children and is considerably higher in white children than in African-American children.2 Overall, ALL represents approximately 25% of all cancers found in children and teens aged <15 years.2

Children with Down syndrome have a 10- to 20-fold increased risk for developing acute leukemia, and Down syndrome is among the strongest risk factors for developing ALL, as well as acute myeloid leukemia.3 Approximately 50% to 60% of children with ALL and Down syndrome have genomic alterations affecting the CRLF2 gene, resulting in an overexpression of the gene’s protein.2 In 35% of these patients, the IKZF1 gene deletions are associated with worse outcomes.2

Overall, the 5-year survival rate for children diagnosed with ALL is 91%.4 Approximately 98% of children with ALL will achieve remission, and approximately 85% of children aged 1 to 8 years with newly diagnosed ALL are expected to be long-term, event-free survivors.2 Children diagnosed with ALL who remain disease-free for ≥5 years are considered “cured” because it is rare for acute leukemia to recur after that time.2

References

  1. American Cancer Society. Key statistics for acute lymphocytic leukemia (ALL). Updated January 8, 2020. www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html. Accessed January 23, 2020.
  2. National Cancer Institute. Childhood acute lymphoblastic leukemia treatment (PDQ)-health professional version. Updated October 22, 2019. www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq. Accessed January 24, 2020.
  3. Matloub Y, Rabin KR, Ji L, et al. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group. Blood Adv. 2019;3:1647-1656.
  4. Cancer.Net. Leukemia - acute lymphoblastic - ALL - childhood - introduction. www.cancer.net/cancer-types/leukemia-acute-lymphoblastic-all-childhood/view-all. Accessed January 24, 2020.
Related Items
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
November 4, 2019 — Oncology News & Updates
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Drug Updates, FDA Updates, Leukemia
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Leukemia
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Web Exclusives published on May 10, 2018 in Leukemia
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Updates, Leukemia
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Updates, Leukemia
Last modified: April 27, 2020